SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.00010000.0%Nov 28 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Scott Pratho who wrote (951)12/24/1997 1:55:00 PM
From: NeuroInvestment  Read Replies (1) of 1359
 
I am constructing my 1998 Overview of prospects for the neuro sector, and obviously Interneuron is one of the more challenging scenarios to sort out. However, a point was made in yesterday's analysts conference call that is potentially very significant vis-a-vis the Redux liability issue. IMS America figures (this is the service that monitors all US prescriptions and sells its analyses to the industry) indicate that only 4% of patients prescribed Redux used it for more than six months. This is critical, because the duration of usage strikes me as a very significant variable; 1)the dearth of valvular anomalies amongst the 11 million Europeans that took it could reflect European tendencies towards short-term usage and the relative absence of cofactors such as phentermine.2) Of the 291 patients in the original FDA database, it now turns out that 15 were Redux-only patients, 2 of whom had valvular anomalies (i.e. 13%, not the initial report of 33%). The two that had anomalies had been on Redux for more than six months, the 11 that did not, were all on Redux for less than six months. Thus we may be talking about an 'at-risk' population of 4% of Redux-only users....a far cry from the crowds predicted by the media, litigators, and our omnipresent shorts.This is before you even come to the question of 'absolute liability' and the limitations that this principle places upon vulnerability to product liability claims, as has been discussed here before. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News